What happened: NHS England has approved Elahere, the first new treatment in over 20 years for chemotherapy-resistant ovarian cancer. This drug offers a life-prolonging option for hundreds of women with hard-to-treat ovarian cancer.
Why it matters:
- Provides a new treatment option for patients with limited alternatives due to chemotherapy resistance.
- Could improve survival and quality of life for women diagnosed at advanced stages of ovarian cancer.
MNN Take: Elahere's approval marks a significant development in ovarian cancer care, addressing a critical need for effective treatments in resistant cases.
Sources: Guardian UK